Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma

The prognosis of patients with advanced hepatocellular carcinoma (HCC) is very poor. The AKT pathway is activated in almost half of HCC cases and in addition, long term exposure to conventional drug treatment of HCC, sorafenib, often results in over-activation of AKT, leading to HCC resistance. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Jilkova, Zuzana Macek, Kuyucu, Ayca Zeybek, Kurma, Keerthi, Ahmad Pour, Séyédéh Tayébéh, Roth, Gaël S., Abbadessa, Giovanni, Yu, Yi, Schwartz, Brian, Sturm, Nathalie, Marche, Patrice N., Hainaut, Pierre, Decaens, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834253/
https://www.ncbi.nlm.nih.gov/pubmed/29541403
http://dx.doi.org/10.18632/oncotarget.24298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834253/
https://www.ncbi.nlm.nih.gov/pubmed/29541403
http://dx.doi.org/10.18632/oncotarget.24298

Ejemplares similares